• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23
    • OncoFAP-GlyPro-MMAE
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23
    • OncoFAP-GlyPro-MMAE
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem

by Lisa Nadal | Nov 28, 2025 | Press Releases, Scientific

Dr. Samuele Cazzamalli, Head of Research at Philochem, will be awarded the Industrial Science Award 2026 from the Swiss Chemical Society His research has focused on the discovery of novel tumor-targeting diagnostic and therapeutic agents through the use of DNA-Encoded...

Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

by Lisa Nadal | Oct 1, 2025 | Events, Scientific

Dr. Emanuele Puca will give an oral presentation entitled: “Antibody-cytokine Fusions for Cancer Therapy: Late-Stage Clinical Results” Dr. Roberto de Luca will give an oral presentation entitled: “Engineering Antibody-Cytokine Fusion Proteins (Immunocytokines) for...

Philogen to attend the PEGS Boston 2025 on May 13-16, 2025

by Lisa Nadal | Mar 22, 2025 | Events, Scientific

Dr. Sebastian Oehler will present Philochem’s recent discovery in the field of prostate cancer under the title “From DNA-Encoded Chemistry to ACP3-Targeted Radioligand Therapeutics against Prostate Cancer” on May 13th (Radiopharmaceutical Therapies track). Follow the...

Philogen to attend AACR 2025 on April 25-30, 2025

by Lisa Nadal | Mar 22, 2025 | Events, Scientific

Claudia Comacchio is presenting a poster about Philochem’s ACP3 antibody therapeutics on April 29, entitled “Generation and in vivo characterization of a novel antibody targeting Prostatic Acid Phosphatase (ACP-3)” [Abstract Number 4781]. Gudrun Thorhallsdottir is...

Philogen to attend World ADC on March 3-6, 2025

by Lisa Nadal | Mar 22, 2025 | Past Events, Scientific

Andrea Galbiati is giving a presentation about Philochem’s FAP-targeted small molecule therapeutics on March 5 (main session), entitled “Detailing Clinical Development of OncoFAP: a Small Molecule Conjugate Targeting Fibroblast Activation Protein in Solid...

Philochem to attend the 23rd Human Proteome Organization World Congress as presenting authors on October 20-24, 2024 in Dresden, Germany)

by Lisa Nadal | Jul 16, 2024 | 2024, Past Events, Scientific

Philochem will participate at the 23rd HUPO Congress in October, presenting two posters: Domenico Ravazza (3rd year Ph.D. student): Mass spectrometry as a quantitative methodology to assess the biodistribution of monoclonal antibodies Lucrezia Principi (2nd year Ph.D....
« Older Entries

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch